- 21297 Foothill Blvd, Ste 203 Hayward, CA 94541 (by appointment only)
- (415) 636-9700
- hello@exxceedwellness.com
Updated August 2026 · Reviewed by Nefretiri Abat, PMHNP-BC
A Spravato denial usually is not a judgment that you do not need treatment. It is far more often a gap in what the record showed. This guide covers the four causes we see most, what to do at each stage of appeal in California, and how to avoid a denial in the first place.
1. Incomplete medication history. Plans want each antidepressant trial documented with drug, dose, duration, and outcome. Many patients have taken more medications than their chart can prove, and the review counts only what is documented. Our guide to what makes an antidepressant trial adequate explains the definitions plans apply.
2. Diagnosis mismatch. Spravato is approved for treatment-resistant depression, as monotherapy or alongside an oral antidepressant, and for depressive symptoms in major depressive disorder with acute suicidal ideation or behavior (in that indication it is given with an oral antidepressant). A request that reads as anxiety or bipolar depression without the right coding will not clear.
3. A plan policy that has not caught up with the label. The FDA approved Spravato as a standalone monotherapy for treatment-resistant depression in January 2025, so pairing it with an oral antidepressant is no longer required by the label. Many plan policies still ask for a concurrent oral antidepressant, and some have begun removing that requirement. If your plan still requires it and your record does not show one, the request can be denied on policy grounds even though the label allows monotherapy. Worth naming directly in an appeal.
4. Administrative gaps. The treatment setting, prescriber, and patient must all be enrolled in the REMS program before the first dose. See Spravato monitoring and REMS requirements.
Read the denial letter first. It states the specific reason and the deadline, and those two facts determine everything that follows.
California parity law requires commercial plans to cover medically necessary mental health treatment on the same terms as physical health care, which is often the backbone of a strong appeal. The same process applies to TMS; see what to do when insurance denies TMS.
The strongest move is a complete first submission. At our Hayward clinic we verify benefits before treatment, assemble the trial history with you, and confirm REMS enrollment before scheduling a first dose. Our Spravato prior authorization guide walks through the full process.
If coverage is resolved but the treatment itself does not help, the pathway continues: see what to do if neither Spravato nor TMS works.
The most common reasons are an incomplete antidepressant trial history, a diagnosis that does not match the labeled indication, missing documentation that the oral antidepressant will be continued alongside Spravato, and administrative errors such as a non-certified treatment setting or a missing REMS enrollment.
Health plans generally allow 180 days from the denial notice to file an internal appeal. If the internal appeal fails, California residents can request an Independent Medical Review through the Department of Managed Health Care, generally within 6 months of the final decision.
A conversation between your prescriber and the plan’s reviewing physician about why the treatment is medically necessary. Many denials are overturned at this stage because the reviewer can ask questions the paperwork did not answer.
It can, which is why the strongest strategy is a complete first submission. If your situation is urgent, ask the plan about an expedited appeal, which carries much shorter deadlines.
This article is educational and is not personal medical or billing advice. Plan rules vary and change over time. If you are in crisis, call or text 988.
